Tech Company Inital Public Offerings
Biodesix IPO
Biodesix was acquired by . The company's stock were listed on 10/28/2020.
Transaction Overview
Company Name
Announced On
10/28/2020
Transaction Type
IPO
Amount
$72,000,000
Proceeds Purpose
Management says it will use the net proceeds from the IPO as follows:(1) to support our commercial expansion of sales, marketing, reimbursement, customer support and business development; (2) to support our product pipeline and research and development; (3) for our Integrated Diagnostics acquisition milestone payment; and (4) for working capital and general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
2970 Wilderness Pl. 100
Boulder, CO 80301
USA
Boulder, CO 80301
USA
Phone
Website
Email Address
Overview
Biodesix (Nasdaq: BDSX) makes blood-based diagnostic tests that help guide treatment of patients with advanced cancer. Our test results are available within 72 hours.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Brunel
Chief Financial Officer
Robin Cowie
Chief Marketing Officer
Bobbi Coffin
Chief Scientific Officer
Linda Traylor
Chief Technical Officer
Heinrich Röder
VP - Bus. Development
Paul Beresford
VP - Human Resources
James Purvis
VP - Operations
Gary Pestano
Browse more venture capital transactions:
Prev: 10/28/2020: GeoLinks venture capital transaction
Next: 10/28/2020: Apeel Sciences venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to record all VC transactions involving tech companies. VC investment data records reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs